Moderna
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company...
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 194
- Registration Number
- NCT05533697
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸George Washington University, Washington, District of Columbia, United States
Use of Wearable Digital Sensors After mRNA Vaccination in Adults
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT05440318
- Locations
- 🇺🇸
Meridian Clinical Research, Lincoln, Nebraska, United States
🇺🇸DM Clinical Research- Texas Center for Drug Development, Houston, Texas, United States
🇺🇸Johnson County Clinical Trials, Lenexa, Kansas, United States
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1860
- Registration Number
- NCT05436834
- Locations
- 🇦🇷
Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, Ciudad Autónoma de Buenos Aires, Ciudad Autónoma De BuenosAires, Argentina
🇦🇷AES - AS - Glenny Corp. S.A. Buenos Aires, Caba, Ciudad Autónoma De Buenos Aires, Argentina
🇦🇷AES - AS - Clinica Mayo de Urgencias, San Miguel de Tucumán, Tucumán, Argentina
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
- Conditions
- Interventions
- First Posted Date
- 2022-06-13
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 6102
- Registration Number
- NCT05415462
- Locations
- 🇦🇷
Expertia S.A- Mautalen Salud e Investigacion, Ciudad Autónoma de Buenos Aires, Argentina
🇦🇷Instituto Médico Río Cuarto, Río Cuarto, Argentina
🇦🇺Emeritus Research, Camberwell, Australia
A Study of Modified mRNA Vaccines in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 308
- Registration Number
- NCT05397223
- Locations
- 🇺🇸
Johnson County Clinical Trials, Lenexa, Kansas, United States
🇺🇸Benchmark Research, Austin, Texas, United States
🇺🇸Tekton Research, Inc, Austin, Texas, United States
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old
- Conditions
- Interventions
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 550
- Registration Number
- NCT05375838
- Locations
- 🇺🇸
Research Centers of America, Hollywood, Florida, United States
🇺🇸DM Clinical Research - CyFair, Houston, Texas, United States
🇺🇸Rochester Clinical Research Inc, Rochester, New York, United States
A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind
- Conditions
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2022-10-13
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1501
- Registration Number
- NCT05367908
- Locations
- 🇺🇸
Evidation Health, San Mateo, California, United States
A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
- Conditions
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 124879
- Registration Number
- NCT05366322
- Locations
- 🇺🇸
Aetion Inc., New York, New York, United States
A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2022-04-18
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 572
- Registration Number
- NCT05333289
- Locations
- 🇺🇸
Heartland Research Associates, LLC, Wichita, Kansas, United States
🇺🇸Foothills Research Center, Phoenix, Arizona, United States
🇺🇸Olympus Family Medicine, Salt Lake City, Utah, United States
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 3800
- Registration Number
- NCT05330975
- Locations
- 🇺🇸
Floridian Clinical Research - ClinEdge - PPDS, Miami Lakes, Florida, United States
🇺🇸Suncoast Research Associates LLC - ERN - PPDS, Miami, Florida, United States
🇺🇸Santa Rosa Medical Centers of Nevada - CCT Research, Las Vegas, Nevada, United States